Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL002 long-term extension in Alzheimer's disease
NL-OMON60169Phase 2Completed
- Sponsor
- Alector
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AL002 in Alzheimer's disease (AD), sponsored by Alector. Started Jul 2024; status: completed.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60169.